The Netherlands caps exenatide prescribing to 11 specialist centres
Efficacy was never the question in this appraisal. Duration of treatment was.
TheCompound Journal
Reporting on incretins, compounding & the peptide supply chain
Page 18 of 33 of this archive, newest first.
Efficacy was never the question in this appraisal. Duration of treatment was.
A proper account of an operation that existed, and of what closing it cost.
What a verification mark would have to carry to be checkable: a date, a lot, a method, a submitter and a link to the report.
Efficacy was never the question in this appraisal. Duration of treatment was.
A proper account of an operation that existed, and of what closing it cost.
Reported from the analysis, not from a warning notice.
A proper account of an operation that existed, and of what closing it cost.
A proper account of an operation that existed, and of what closing it cost.
A proper account of an operation that existed, and of what closing it cost.
Efficacy was never the question in this appraisal. Duration of treatment was.
A proper account of an operation that existed, and of what closing it cost.
Duplicate submissions under different names test within-laboratory repeatability, which is a different quantity from between-laboratory reproducibility.
Efficacy was never the question in this appraisal. Duration of treatment was.
Reported from the analysis, not from a warning notice.
Reported from the analysis, not from a warning notice.
Reported from the analysis, not from a warning notice.
Efficacy was never the question in this appraisal. Duration of treatment was.
Efficacy was never the question in this appraisal. Duration of treatment was.
A result on one vial generalises to a batch only if the vial was drawn in a way that makes it representative — and nobody records how it was drawn.
Efficacy was never the question in this appraisal. Duration of treatment was.